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The compound, 2,3,7,8-tetrachlorodibenzo-
p-dioxin (TCDD, or dioxin) is a widespread 
environmental contaminant (Birnbaum 1994, 
1995; Zook and Rappe 1994). In animals, 
TCDD is a potent multisite carcinogen and 
has been shown to disrupt multiple endocrine 
pathways [Birnbaum 1994, 1995; Birnbaum 
and Fenton 2003; International Agency for 
Research on Cancer (IARC) 1997]. In 1997, 
the IARC classified TCDD as carcinogenic 
to humans (Group 1), based on limited evi-
dence of carcinogenicity in humans, sufficient 
evidence in animals, and strong evidence in 
humans and animals for a common mecha-
nism of action via initial binding to the aryl 
hydrocarbon receptor (AhR) (IARC 1997). 
Binding of the AhR leads to changes in gene 
expression, cell replication, and apoptosis. In 
2009, IARC reconfirmed the classification of 
TCDD as a Group 1 carcinogen, citing suf-
ficient epidemiological evidence for all cancers 
combined (Baan et al. 2009). This conclu-
sion was based on male occupational cohort 
studies of increased mortality from all cancers 
combined, but no particular cancer sites were 
predominant.
Animal studies report a higher incidence 
of tumors associated with TCDD exposure 
in females than in males (Kociba et al. 1978). 
However, few studies in humans have inves-
tigated cancer in women associated with 
TCDD exposure. Two occupational cohort 
studies of workers employed in the production 
of chlorophenoxy herbicides have examined 
the relationship between TCDD exposure 
and cancer risk in females (Flesch-Janys et al. 
1999; Kogevinas et al. 1993, 1997; Manz 
et al. 1991). Although limited by small sample 
size and lack of individual exposure data, both 
studies report increased risks for mortality or 
incidence from all cancers combined in the 
subset of female workers who were employed 
in the production of TCDD-contaminated 
phenoxy herbicides (Flesch-Janys et al. 1999; 
Kogevinas et al. 1993; Manz et al. 1991).
The results of the occupational cohort 
  studies are supported by the most recent 
  follow-up of the Seveso population (Consonni 
et al. 2008; Pesatori et al. 2009). On 10 July 
1976, an explosion at a trichlorophenol manu-
facturing plant near Seveso, Italy, resulted in the 
highest TCDD levels known in human residen-
tial populations (Mocarelli et al. 1988). Up to 
30 kg TCDD was deposited over the surround-
ing 18-km2 area (Di Domenico et al. 1980), 
which was divided into exposure zones (A, B, R, 
non-ABR) based on TCDD   measurements in 
soil. After 20 years (1976–1996), cancer inci-
dence was non  significantly increased in resi-
dents of the most exposed zone, zone A, for 
a wide range of cancer sites, including breast 
cancer (Pesatori et al. 2009). After 25 years 
(1976–2001), all cancer mortality was signifi-
cantly increased in zone A when the analysis 
was limited to deaths occurring ≥ 20 years after 
the explosion (Consonni et al. 2008). Exposure 
estimates for these ecologic cohort studies were 
based on zone of residence and thus lacked 
individual-level exposure data.
The Seveso Women’s Health Study 
(SWHS), a historical cohort study of the 
female population residing around Seveso 
at the time of the explosion in 1976, rep-
resents the largest female population with 
known individual TCDD exposure (Eskenazi 
et al. 2000). Previously, using data from the 
SWHS, we examined the association between 
individual-level TCDD exposure, measured in 
archived serum collected soon after the explo-
sion, and cancer risk 20 years later (Warner 
et al. 2002). We found a non  significant 
increased risk for all cancer incidence [hazard 
ratio (HR) = 1.7; 95% confidence interval 
(CI): 0.90, 3.4] and a significant increased risk 
for breast cancer incidence (HR = 2.1; 95% 
CI: 1.0, 4.8) associated with a 10-fold increase 
in individual serum TCDD levels. In 1996, 
however, the SWHS cohort was relatively 
young, averaging 40 years of age. Herein we 
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Ba c k g r o u n d: 2,3,7,8-Tetrachlorodibenzo-para-dioxin (TCDD), a widespread environmental 
  contaminant, disrupts multiple endocrine pathways. The International Agency for Research on 
Cancer classified TCDD as a known human carcinogen, based on predominantly male occupational 
studies of increased mortality from all cancers combined.
oBjectives: After a chemical explosion on 10 July 1976 in Seveso, Italy, residents experienced some 
of the highest levels of TCDD exposure in a human population. In 1996, we initiated the Seveso 
Women’s Health Study (SWHS), a retrospective cohort study of the reproductive health of the 
women. We previously reported a significant increased risk for breast cancer and a non  significant 
increased risk for all cancers combined with individual serum TCDD, but the cohort averaged only 
40 years of age in 1996. Herein we report results for risk of cancer from a subsequent follow-up of 
the cohort in 2008.
Me t h o d s : In 1996, we enrolled 981 women who were 0–40 years of age in 1976, lived in the 
most contaminated areas, and had archived sera collected near the explosion. Individual TCDD 
concentration was measured in archived serum by high-resolution mass spectrometry. A total of 833 
women participated in the 2008 follow-up study. We examined the relation of serum TCDD with 
cancer incidence using Cox proportional hazards models.
re s u l t s: In total, 66 (6.7%) women had been diagnosed with cancer. The adjusted hazard ratio 
(HR) associated with a 10-fold increase in serum TCDD for all cancers combined was significantly 
increased [adjusted HR = 1.80; 95% confidence interval (CI): 1.29, 2.52]. For breast cancer, the 
HR was increased, but not significantly (adjusted HR = 1.44; 95% CI: 0.89, 2.33).
co n c l u s i o n s: Individual serum TCDD is significantly positively related with all cancer incidence 
in the SWHS cohort, more than 30 years later. This all-female study adds to the epidemiologic evi-
dence that TCDD is a multisite carcinogen.
key w o r d s : cancer, cohort studies, dioxins, environmental carcinogens, female, neoplasms, tetra-
chlorodibenzodioxin. Environ Health Perspect 119:1700–1705 (2011).  http://dx.doi.org/10.1289/
ehp.1103720 [Online 2 August 2011]Dioxin exposure and cancer risk
Environmental Health Perspectives  •  v o l u m e  119 | n u m b e r 12 | December 2011  1701
report results for risk of cancer incidence with 
TCDD exposure from a subsequent follow-up 
of the cohort in 2008.
Methods
Study population. The SWHS is a historical 
cohort study of the female population resid-
ing around Seveso at the time of the explo-
sion in 1976. Details of the study design are 
presented elsewhere (Eskenazi et al. 2000). 
Briefly, eligible women were 0–40 years of 
age in 1976, had resided in one of the most 
highly contaminated zones, A or B, at the time 
of the explosion, and had adequate stored sera 
collected soon after the explosion. Enrollment 
began in March 1996 and was completed 
in July 1998 for study I. Of the 1,271 eli-
gible women, 33 women were deceased or 
ill, 17 women were not reachable, and 240 
refused to participate. A total of 981 (80%) 
participated in the first follow-up.
In 2008, we initiated a second follow-up 
study of the SWHS cohort (study II). 
Enrollment began in April 2008 and was 
completed in December 2009. Of the 981 
eligible women, 16 (1.6%) were deceased and 
36 (3.7%) could not be located or contacted. 
Of the remaining women who could be con-
tacted, 833 (84.9%) agreed to participate.
Procedure. Details of the study procedure 
for the first follow-up study (study I) are pre-
sented elsewhere (Eskenazi et al. 2000). Briefly, 
participation included written informed con-
sent, fasting blood draw, personal interview, 
and for a subset, a gynecologic examination 
and transvaginal ultrasound. Additional data 
were abstracted from medical records.
Participation in the second follow-up study 
(study II) included written informed consent, 
fasting blood draw, anthropometric and blood 
pressure measurements, personal interview, 
and for a subset, a bone density examination. 
Additional data were also abstracted from 
medical records.
For both study I and II, personal inter-
views were conducted by trained nurse-
interviewers who were blinded to serum 
TCDD levels and zones of residence. During 
the interview, detailed information was col-
lected on the reproductive and medical his-
tory of the women as well as demographic 
and lifestyle factors. Reproductive informa-
tion collected included reproductive diseases, 
pregnancy history, history of hormone use, 
menopause status, medications use, and fam-
ily history of cancer. Current information on 
other risk factors included use of cigarettes, 
alcohol or caffeine, calcium and other sup-
plements, and social class factors (education, 
occupation, income). In addition, in study II, 
the European Prospective Investigation into 
Cancer and Nutrition (EPIC)–Italy food fre-
quency questionnaire was administered (Pisani 
et al. 1997).
Medical history information obtained on 
the questionnaire included a diagnosis of can-
cer. During the interview, each woman was 
asked a series of cancer questions following the 
format, including “Has a doctor ever told you 
that you had breast cancer?” If she answered 
“yes” to any of the cancer questions, past med-
ical records were obtained and were reviewed 
by a cancer pathologist who was blinded to the 
woman’s exposure. The death certificates were 
requested for all 16 deaths, and if cancer was 
indicated as a cause of death (n = 14), medical 
records were also requested. This study was 
approved by the institutional review boards of 
the participating institutions.
Laboratory analyses. TCDD was measured 
in archived sera by high-resolution gas chro-
matography/high-resolution mass spectrom-
etry methods (Patterson et al. 1987). Values 
are reported on a lipid-weight basis in parts 
per trillion (ppt) (Akins et al. 1989). Details of 
serum sample selection are presented elsewhere 
(Eskenazi et al. 2000, 2004). Briefly, from 
the archived serum samples collected between 
1976 and 1985 and stored at –20°C, we pref-
erentially selected for analysis the first sample 
available that was collected between 1976 and 
1981 and was of adequate volume (> 0.5 mL) 
to measure TCDD. We measured TCDD in 
sera collected in 1976 or 1977 for 894 women 
(91%), between 1978 and 1981 for 59 women 
(6%), and in 1996 or 1997 for 28 women 
(3%) with insufficient volume in earlier sam-
ples. For women with detectable post-1977 
TCDD measurements > 10 ppt, the TCDD 
exposure level was back-extrapolated to 1976 
using the first-order kinetic model (Pirkle 
et al. 1989) for women who were older than 
16 years in 1976 (n = 40) or the Filser model 
(Kreuzer et al. 1997) otherwise (n = 30). For 
eight women whose post-1977 TCDD values 
were detectable but ≤ 10 ppt, the measured 
value was used. For non  detectable values (n 
= 96), a serum TCDD level of one-half the 
detection limit was assigned (Hornung and 
Reed 1990). For the study median serum 
sample weight of 0.65 g, the median limit of 
detection was 18.8 ppt, lipid-adjusted.
Statistical analyses. Serum TCDD 
was analyzed both as a continuous variable 
(log10TCDD) and a four-category variable. 
The cut point for the lowest group was set at 
≤ 20 ppt, because 15–20 ppt was the average 
TCDD level in serum pools collected from 
unexposed Italian women in 1976 (Eskenazi 
et al. 2004). The three remaining categories 
were defined by calculating tertiles of exposure 
> 20 ppt, producing groups ≤ 20, 20.1–47.0, 
47.1–135.0, and > 135 ppt.
We used Cox proportional hazards mod-
eling for the main analyses. Age was the 
underlying time variable, with entry defined 
as the age of the subject on the explosion 
date, 10 July 1976, and exit defined as her age 
at cancer diagnosis or censoring (death, last 
follow-up). Women who refused or were not 
able to be located were censored at the age at 
last follow-up (1996–1998). We report the 
measure of effect as the HR and 95% CI.
We examined the effect of a broad range of 
potential confounders identified in the cancer 
and breast cancer literature (American Cancer 
Society 2010; Brody and Rudel 2003; Hulka 
and Moorman 2001; Key et al. 2001; Salehi 
et al. 2008; Travis and Key 2003). We consid-
ered education, marital status, gravidity, parity, 
age at first full-term pregnancy, lactation his-
tory, family history of breast cancer in a first-
degree relative, age at menarche, body mass 
index (BMI), weight, height, oral contraceptive 
(OC) use, menarche status at explosion, time 
from explosion to first full-term pregnancy, 
age at explosion, menopause status, age at 
menopause, hormone replacement therapy use, 
history of thyroid disease, physical inactivity, 
smoking, and alcohol consumption. Covariate 
information for each woman was based 
on data collected at her last follow-up. We 
also considered age at menopause as a time-
  dependent variable. Covariates were included 
in Cox models if they changed the coefficient 
for log10TCDD by at least 10% or if they were 
independently associated with the cancer out-
come at p < 0.10. We also considered possible 
interaction of menarche status at explosion.
In sensitivity analyses, we repeated the 
final models for cancer and breast cancer, 
stratifying on study follow-up period (study I: 
1976–1996; study II: 1997–2009), on time 
between initial exposure and disease diagnosis 
or latency period (0–10 years; 11–20 years; 
21–32 years), on menopause status at diag-
nosis, and on estrogen or progesterone recep-
tor status. We also repeated the final models, 
excluding women whose individual TCDD 
level was measured in serum collected after 
1977 and excluding women with individ-
ual TCDD levels derived by extrapolation. 
Finally, we repeated the final models assuming 
all non  participants (refusals, loss to follow-up) 
in study II were non  cases.
Standard errors were estimated using the 
robust Huber–White sandwich estimator. The 
proportional hazards assumption was tested 
using scaled Schoenfeld residuals. We con-
ducted tests for linear trend by including cate-
gorical TCDD as a continuous term in the 
models. All statistical analyses were performed 
using STATA 11.0 (version 11.0; StataCorp, 
College Station, TX, USA).
Results
Table 1 presents the distribution of TCDD 
exposure by select characteristics of the 
SWHS cohort. On the date of the explo-
sion, 232 women (24%) were < 10 years of 
age, and 284 (29%) were premenarcheal. At 
last follow-up, the average (± SD) age of the Warner et al.
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cohort was 50.8 (± 11.8) years, about half of 
the women (51%) were post  menopause, and 
152 (16%) were nulliparous. The mean age 
at first pregnancy for the 829 parous women 
was 25.4 (± 4.6) years, and 711 (86%) had 
ever lactated. About 10% of women reported a 
family history of breast cancer in a first-  degree 
relative (mother, sister, daughter). Most (63%) 
women had never regularly smoked or con-
sumed alcohol. The average BMI at last fol-
low-up was 26.4 (± 5.4) kg/m2, and 22% were 
obese. Serum TCDD levels were higher among 
women who were youngest or premenarche 
at explosion. TCDD levels were also higher 
among women who at last follow-up were 
nulliparous, current OC users, never married, 
more educated, or pre  menopause, but these are 
all also age-related characteristics.
In total, 66 women (6.7%) in the SWHS 
cohort had been diagnosed with cancer. Of 
the 66 incident cases, 21 were diagnosed by 
the first follow-up (1996–1998), and 45 were 
diagnosed by the second follow-up (2008–
2009). Of the 66 cases, 65 (98%) were con-
firmed by pathology and one (2%) by surgery 
report alone. The average age of cases (n = 66) 
at diagnosis was 48.8 (± 11.3) years and at 
explosion was 25.5 (± 10.9) years. The cases 
were diagnosed an average of 23.4 (± 7.2) years 
after the explosion, with the shortest inter-
val being 7 years. The geometric mean (SD) 
serum TCDD level for the 66 cancer cases 
[95.3 (4.0) ppt, lipid-adjusted] is somewhat 
greater than the concentration for the non-
cases [n = 915; 67.9 (4.2)] [analysis of variance 
(ANOVA) for log10TCDD: p = 0.06].
The distribution of cancer sites among 
the 66 cases is presented in Table 2. Breast 
cancer (n = 33) was the most frequent site, 
representing half of the cases. Thyroid cancer 
(n = 7) was the second most frequent site. The 
remaining cases were represented by a wide 
variety of cancer sites.
All breast cancers were confirmed by 
pathology. The average age of breast can-
cer cases at explosion was 26.4 (± 8.7) years, 
with a range from 10 to 39 years. The aver-
age age at diagnosis was 48.3 (± 8.5) years, 
with a range from 31 to 69 years. The aver-
age interval between explosion and diagnosis 
was 21.9 (± 7.3) years; the shortest interval 
was 8 years. Most of the 33 breast cancer cases 
(n = 18; 55%) were diagnosed pre  menopause. 
For the breast cancer cases for whom recep-
tor status of tumors was available, 20 of 23 
(87%) were estrogen receptor (ER)–positive, 
19 of 22 (86.4%) were progesterone receptor 
(PR)–positive, and 6 of 12 (50%) were human 
epidermal growth factor receptor 2 (HER2)–
positive. Of the 22 cases who had both ER and 
PR data, 82% were ER+PR+. There was no 
significant difference in receptor status of pre- 
and post  menopause cases.
Because of the small numbers of cases of 
specific cancer types, in multivariate analysis we 
were able to examine only the relation of serum 
TCDD levels to all cancers combined and to 
breast cancer. For thyroid cancer, in a univariate 
Cox model, the unadjusted HR associated with 
a 10-fold increase in TCDD (log10TCDD) 
was 2.1 (95% CI: 0.6, 6.7). Table 3 presents 
the unadjusted and adjusted results of Cox pro-
portional hazards modeling for the association 
between lipid-adjusted serum TCDD level and 
all cancers combined and breast cancer risk.
For analysis of all cancers combined, in 
single-covariate Cox models cancer risk was 
positively associated with premenarche status 
at explosion, never married, current alcohol 
consumption, physical inactivity, lower gra-
vidity, lower parity, and never lactating. As 
presented in Table 3, after adjusting for age 
at explosion and marital status, the adjusted 
HR associated with a 10-fold increase in 
TCDD (log10TCDD) for all cancers com-
bined remained significantly increased to 1.80 
(95% CI: 1.29, 2.52). When TCDD was 
Table 1. Distribution of 1976 serum TCDD levels (parts per trillion, lipid-adjusted) by select characteristics in the SWHS, Italy, 1976–2009.
aNumbers do not add to 100% of total because of missing data. bParous women only. *p < 0.05 (ANOVA significant difference in log10TCDD by covariate).
Characteristic n (%)
TCDD (ppt) 
[median (interquartile range)]
Total  981 (100.0) 55.9 (28–157)
Zone of residence*
A 167 (17.0) 272.0 (93–883)
B 814 (83.0) 47.1 (25–106)
Age at explosion (years)*
0–10 232 (23.7) 165.0 (61–344)
11–20 279 (28.4) 48.8 (24–100)
21–30 241 (24.6) 43.8 (23–101)
31–40 229 (23.3) 45.2 (28–99)
Menarche status at explosion*
Premenarche 284 (28.9) 142.5 (57–300)
Postmenarche 697 (71.1) 44.4 (24–97)
Age at menarche (years)a
< 12 228 (23.2) 57.7 (29–167)
12–13 461 (47.0) 54.8 (26–156)
> 13 289 (29.5) 55.8 (30–150)
Parity*
0 152 (15.5) 97.6 (36–267)
1–2 648 (66.1) 54.9 (27–151)
≥ 3 181 (18.5) 43.2 (25–92)
Age at first full-term pregnancy (years)b,*
< 20 67 (8.1) 32.7 (18–74)
20–25 396 (47.8) 45.1 (26–106)
> 25 366 (44.2) 66.7 (32–196)
Lactation historyb
Never 118 (14.2) 45.1 (28–122)
Ever 711 (85.8) 52.9 (27–139)
Menopause statusa,*
Premenopause 484 (49.3) 75.0 (33–213)
Postmenopause 496 (50.6) 45.2 (24–105)
HRT useb
Never 867 (88.4) 59.4 (29–165)
Ever 87 (8.9) 45.2 (27–92)
Characteristic n (%)
TCDD (ppt) 
[median (interquartile range)]
Family history of breast cancer
No 877 (89.4) 57.6 (28–159)
Yes 104 (10.6) 51.6 (29–121)
Education*
≤ Required 651 (66.4) 49.6 (26–120)
High school 288 (29.4) 76.5 (34–256)
> High school 42 (4.3) 72.4 (30–251)
Marital status*
Never 76 (7.8) 140.3 (48–353)
Ever 905 (92.3) 53.3 (28–142)
Oral contraceptive use*
Never 443 (45.2) 46.5 (27–117)
Former 453 (46.2) 66.2 (31–165)
Current 85 (8.7) 112.0 (37–272)
Cigarette smoking
Never 619 (63.1) 54.8 (28–156)
Former 194 (19.8) 63.3 (29–163)
Current 168 (17.1) 55.1 (29–155)
Alcohol use
Never 618 (63.0) 53.5 (28–153)
Former 44 (4.5) 59.7 (30–122)
Current 319 (32.5) 61.1 (29–164)
BMI (kg/m2)*
Underweight (< 18.5) 26 (2.6) 116.5 (33–352)
Normal (18.5–24.9) 437 (44.6) 71.4 (37–185)
Overweight (25–30) 302 (30.8) 45.5 (24–119)
Obese (> 30) 216 (22.0) 45.9 (25–119)
Physical activity*
Active 326 (33.2) 49.3 (26–117)
Moderately active 297 (30.3) 70.0 (30– 214)
Inactive 358 (36.5) 57.9 (28–164)Dioxin exposure and cancer risk
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considered as a categorical variable, there was 
still evidence of a significant dose–response 
trend (p = 0.002). Compared with the low-
est exposure group (≤ 20 ppt), the adjusted 
HR (95% CI) for the three dose groups, 
20.1–47 ppt, 47.1–135 ppt, and > 135 ppt, 
were 1.23 (0.48, 3.16), 2.50 (1.02, 6.09), and 
2.77 (1.11, 6.90), respectively. We found no 
evidence of interaction by menarche status at 
explosion (p = 0.89). When stratified by zone, 
although the number of cases from zone A 
is small, we found no difference in risk of all 
cancers associated with serum TCDD   levels 
by residence in zone A (n = 13; adjusted HR 
= 1.55; 95% CI: 0.86, 2.80) or zone B (n = 
53; adjusted HR = 2.30; 95% CI: 1.32, 3.99). 
The p-value for an interaction of TCDD and 
zone was p = 0.27.
For the breast cancer analysis, in single-
  covariate Cox models, breast cancer risk was pos-
itively associated with younger age of menarche, 
lower gravidity, lower parity, never lactating, 
older age at first pregnancy, and family history 
of breast cancer. As presented in Table 3, after 
adjusting for parity and family history of breast 
cancer in a first-degree relative, the adjusted 
HR (95% CI) for breast cancer associated with 
a 10-fold increase in exposure (log10TCDD) 
was non  significantly increased to 1.44 (0.89, 
2.33). When TCDD was categorized, there was 
some evidence of a dose response, but it was not 
statistically significant (p = 0.09). Compared 
with the lowest exposure group (≤ 20 ppt), the 
adjusted HR (95% CI) for the three higher 
dose groups were 0.94 (0.28, 3.14), 1.95 (0.64, 
5.95), and 1.98 (0.62, 6.32), respectively.
If we consider the group “all cancers 
combined excluding breast cancer” (n = 33), 
the adjusted HR (95% CI) associated with a 
10-fold increase in exposure (log10TCDD) 
was significantly increased to 2.08 (1.34, 
3.23). When TCDD was categorized, there 
was evidence of a significant dose–response 
trend (p = 0.02). Compared with the lowest 
exposure group (≤ 20 ppt), the adjusted HRs 
(95% CI) for the three higher dose groups 
were 1.78 (0.38, 8.33), 3.29 (0.72, 14.92), 
and 3.96 (0.87, 18.24), respectively.
Table 4 presents the results of Cox propor-
tional hazards models for all cancers and breast 
cancer, stratified by study follow-up period 
(study I: 1976–1996; study II: 1997–2009) 
and by latency period (0–10 years, 11–20 
years, 21–32 years). Although the small num-
bers of cancer cases within strata limit power, 
the HRs presented for all cancer incidence 
do not differ by study follow-up period or 
latency period. For breast cancer, however, the 
significant increased risk reported for breast 
cancer incidence during study I is diminished 
in the last decade of follow-up and is no lon-
ger significant. Further, in sensitivity analyses, 
we found no difference in risk by menopause 
status at diagnosis or receptor status, but the 
numbers are small (data not shown).
We repeated the final models, first lim-
iting the analysis to the 894 women with 
TCDD measured in samples collected in 
1976 or 1977, and then excluding 78 women 
with extrapolated TCDD measures, and the 
results were not different (data not shown). 
Finally, we assumed all non  participants (refus-
als, loss to follow-up) were non  cases, and the 
results did not change (data not shown).
Discussion
We observed a statistically significant, dose-
  related increased risk in overall cancer inci-
dence associated with individual serum 
TCDD level in the SWHS. Specifically, we 
Table 3. HRs from Cox proportional hazards model for association between lipid-adjusted serum TCDD levels and all cancer and breast cancer risk over 32 years 
of follow-up, SWHS, Italy, 1976–2009.
All cancers Breast cancer
Exposure Cases/total  HR (95% CI)
Adjusted HRa 
(95% CI) Cases/total HR (95% CI)
Adjusted HRb 
(95% CI)
Log10TCDDc (ppt) 66/981 1.86 (1.34, 2.59) 1.80 (1.29, 2.52) 33/981 1.49 (0.93, 2.38) 1.44 (0.89, 2.33)
p < 0.001 p = 0.001 p = 0.10 p = 0.13
TCDD (ppt)
≤ 20 6/154 1.00 1.00 4/154 1.00 1.00
20.1–47.0 14/276 1.16 (0.45, 3.02) 1.23 (0.48, 3.16) 7/276 0.91 (0.27, 3.08) 0.94 (0.28, 3.14)
47.1–135.0 25/278 2.53 (1.04, 6.18) 2.50 (1.02, 6.09) 13/278 2.07 (0.68, 6.30) 1.95 (0.64, 5.95)
> 135 21/273 2.92 (1.18, 7.24) 2.77 (1.11, 6.90) 9/273 2.04 (0.64, 6.48) 1.98 (0.62, 6.32)
p-Trend = 0.001 p-Trend = 0.002 p-Trend = 0.07 p-Trend = 0.09
aAdjusted for marital status and age at explosion. bAdjusted for parity and family history of breast cancer in a first-degree relative. cHR for a 10-fold increase in serum TCDD concentration.
Table 4. HRs from Cox proportional hazards model for association between lipid-adjusted serum (log10) TCDD levels and all cancer risk and breast cancer risk, 
stratified on follow-up period, SWHS, Italy, 1976–2009.
All cancers Breast cancer
Follow-up Cases p-y
Unadjusted HRa 
(95% CI) p Cases p-y
Unadjusted HRa 
(95% CI) p
1976–2009 66 29,722 1.86 (1.34, 2.59) < 0.001 33 29,838 1.49 (0.93, 2.38) 0.10
Study I (1976 to 1996–1998) 21 20,118 1.71 (0.93, 3.14) 0.08 15 20,168 2.13 (1.11, 4.09) 0.02
Study II (1996–1998 to 2008–2009) 45 9,604 1.83 (1.25, 2.67) 0.002 18 9,670 1.12 (0.61, 2.06) 0.71
 0–10 years (1976–1986) 6 9,802 2.39 (1.13, 5.06) 0.02 3 9,808 2.91 (0.90, 9.44) 0.08
11–20 years (1987–1996) 13 9,699 1.61 (0.72, 3.59) 0.25 10 9,737 2.23 (1.09, 4.56) 0.03
21–32 years (1997–2009) 47 10,221 1.77 (1.21, 2.58) 0.003 20 10,293 1.06 (0.58, 1.93) 0.86
p-y, person-years. 
aHR for a 10-fold increase in serum TCDD concentration.
Table 2. Distribution of cancer cases, SWHS, Italy, 
1976–2009.
Cancer site (ICD-9 code)a n (%)
All cancers 66 (100)
Digestive organs, peritoneum (150–159) 8 (12.1)
Esophagus (150) 1
Stomach (151) 2
Colon (153) 3
Rectum (154) 1
Other digestive (159)  1
Respiratory, intrathoracic organs (160–165) 2 (3.0)
Lung (162) 2
Bone, connective tissue, skin, breast (170–175) 36 (54.5)
Melanoma of skin (172) 3
Breast (174) 33
Genitourinary organs (179–189) 8 (12.1)
Cervix (180) 1
Placenta (181) 1
Uterus (182) 3
Ovary (183) 2
Kidney (189) 1
Other and unspecified sites (190–199) 9 (13.6)
Thyroid (193) 7
Ill-defined (199) 2
Lymphatic, hematopoietic tissue (200–208) 3 (4.5)
Lymphoma (202) 2
Myeloid leukemia (205) 1
aInternational Classification of Diseases, 9th Revision 
(World Health Organization 1980). Warner et al.
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reported a significant increased HR of 1.8 
associated with a 10-fold increase in serum 
TCDD. This result is similar to our previous 
observation, although the association was not 
statistically significant in the earlier follow-up 
in 1996–1998 (Warner et al. 2002).
The validity of the findings is strengthened 
by the fact that the results did not change 
and remained significant after adjusting for 
potential confounding factors. Participation 
in study II was high (> 85%) 12 years after 
study I and > 30 years after the explosion. In 
addition, loss to follow-up was low (3.7%). 
Participants and non  participants (refusals, loss 
to follow-up) did not differ in terms of age at 
explosion or serum TCDD level.
The results of this study are consistent with 
those from earlier studies suggesting an associa-
tion but lacking individual exposure data. The 
two occupational cohort studies of workers 
employed in the production of chloro  phenoxy 
herbicides both reported increased risks for 
mortality and incidence from all cancers in the 
subset of female workers who were employed 
in the production of TCDD-contaminated 
phenoxy herbicides (Flesch-Janys et al. 1999; 
Kogevinas et al. 1993).
The results are also consistent with those 
reported for zone A, but not zone B, in the 
most recent cancer incidence study of the 
larger Seveso population (Pesatori et al. 2009). 
After 20 years (1976–1996), non  significant 
increased risks for cancer incidence were 
reported in zone A for a wide range of cancers. 
In zone A, after a 15-year latency, all cancer 
incidence for males and females together was 
non  significantly increased (n = 19; rate ratio 
(RR) = 1.27; 95% CI: 0.81, 2.00), but sex-
specific risks were not presented. Our results, 
however, are not consistent with those reported 
for zone B, which, in contrast to zone A, after 
a 15-year latency had no increase in all can-
cer incidence for males and females together 
(n = 92; RR = 1.02; 95% CI: 0.83, 1.26). The 
lack of consistency for zone B is likely attrib-
utable, in part, to exposure misclassification. 
Individual serum TCDD measurements from 
the SWHS suggest a wide range of individ-
ual TCDD exposures within zones (Eskenazi 
et al. 2004). Exposure misclassification based 
on zone of residence would be expected to 
be non  differential, potentially resulting in an 
underestimate of effect. Although the number 
of cases from zone A is small in our study, 
we found no difference between zone A and 
zone B in risk of cancer associated with serum 
TCDD levels.
The results are also somewhat consistent 
with the most recent cancer mortality study 
of the larger Seveso population (Consonni 
et al. 2008). After 25 years of follow-up 
(1976–2001), the number of cancer deaths in 
zone A was small (n = 42), but with a 20-year 
latency, mortality from cancer among zone A 
women was non  significantly increased (n = 5; 
RR = 1.17; 95% CI: 0.49, 2.83). Similar data 
were not presented for zone B women. There 
is likely little overlap in cases between the mor-
tality study and SWHS. The SWHS cohort 
included women who were 0–40 years of age 
in 1976, whereas the larger Seveso cohort 
included women who were 20–74 years of 
age. In addition, we included incident cases 
diagnosed between 1976 and 2009; 14 of the 
SWHS women were deceased, but only one 
case died before 2001, the end of follow-up for 
the mortality study (Consonni et al. 2008).
An advantage of SWHS is that we were 
able to examine the relationship between 
serum TCDD concentration and cancer inci-
dence, not mortality, thus eliminating poten-
tial biases associated with variations in disease 
survival. In addition, we were able to collect 
information on confounding factors during 
the interview that were not available in the 
mortality study. Finally, we were able to meas-
ure individual serum TCDD concentrations 
near the time of exposure, thus minimizing 
exposure misclassification.
A limitation of the SWHS study is 
the small number of cancer cases (n = 66). 
However, this number is greater than the 
number in any other single study of cancer in 
TCDD-exposed women (Flesch-Janys et al. 
1999; Kogevinas et al. 1993; Pesatori et al. 
2009). These other studies, with numbers of 
cases ranging from 9 to 57, reported increased 
cancer risks similar to the HRs reported here. 
These studies classified exposure based on job 
history, company production records, and, for 
a subset of workers, TCDD in serum or adi-
pose measured many years after last exposure.
Although we observed a wide range of 
cancers in this study, only breast cancer had 
enough cases for an examination of the associ-
ation with TCDD. We found a non  significant 
increase in the HR (HR = 1.44; 95% CI: 
0.89, 2.33) associated with a 10-fold increase 
in serum TCDD over the 32-year follow-up 
period. Our earlier observation of a signifi-
cantly increased risk of breast cancer with 
20 years of follow-up (Warner et al. 2002) 
was not sustained with the additional 12 years 
of data. In categorical analysis, although not 
significant, the highest risks were observed for 
the highest dose groups.
The results for breast cancer in this study 
are somewhat consistent with those from the 
20-year incidence study of the larger Seveso 
population, which reported a non  significant 
increased risk for breast cancer in zone A 
(n = 8; RR = 1.43; 95% CI: 0.71, 2.87), but 
not zone B (n = 30; RR = 0.85; 95% CI: 
0.59, 1.22) (Pesatori et al. 2009). Pesatori 
et al. (2009) found no difference in risk by 
age at diagnosis of breast cancer before or 
after 50 years of age, a proxy for menopause 
status (< 50: n = 3; RR = 1.50; 95% CI: 0.48, 
4.67 vs. ≥ 50: n = 5; RR = 1.39; 95% CI: 
0.58, 3.36). Consistent with that report, we 
found no difference in risk of breast cancer 
with TCDD exposure by menopause status 
at diagnosis. The two studies, however, are 
not directly comparable. The SWHS cohort 
is younger; at explosion, the 33 breast cancer 
cases in SWHS averaged 26.4 years of age, 
whereas the 8 breast cancer cases in zone A 
in the study by Pesatori et al. (2009) were 
20–49 years of age.
When we compared the observed breast 
cancer incidence in the SWHS cohort with 
that expected for the area using 1985–2009 
age-specific breast cancer incidence rates from 
the Lombardy Cancer Registry in Italy (Italian 
Association of Cancer Registries 2010), the 
expected number of breast cancer cases would 
be 27; we found 33 for an overall standard-
ized incidence ratio for the 981 women of 
1.22. Further, the observed excess of cases 
was highest in the 45- to 49-year age group 
(10 observed vs. 5 expected).
Of the breast cancer cases for whom recep-
tor status data were available, the distribution 
of ER+ and PR+ but not HER2+ was simi-
lar to that reported by the Tuscany Cancer 
Registry among all the invasive breast cancer 
cases diagnosed during the period 2004–2005 
(Caldarella et al. 2011). Given the limited 
number of cases (n = 12) with HER2+ data 
available for SWHS, however, it is difficult to 
determine whether there is any difference in 
receptor status.
It is possible the increased risk for breast 
cancer observed in earlier decades of follow-up 
reflects a mechanism of action of TCDD as a 
cancer promoter. It is also worth noting that 
the cohort has not yet been followed to the 
time of greatest onset of breast cancer—post-
menopause. With additional follow-up, we will 
be able to better discern whether the window 
of increased risk for breast cancer observed in 
the earlier follow-up period is in fact past.
Additional follow-up is also needed for 
the observed cancers other than breast. There 
is evidence in animals of an effect of TCDD 
on thyroid function, including an increase in 
thyroid follicular cell hyperplasia (Nishimura 
et al. 2002, 2003; Yoshizawa et al. 2010). The 
number of thyroid cancer cases is small, but 
it is noteworthy that the observed increase 
in HR is consistent with the animal studies. 
We also observed two cases of lung cancer 
(one in a non  smoker) and three cases of lym-
phatic and hematopoietic cancers, both types 
of cancer previously reported to be associ-
ated with TCDD exposure (Consonni et al. 
2008; IARC 1997; Pesatori et al. 2009), but 
we were unable to examine the relation of 
TCDD because of the small number of cases.
In summary, we have shown that indi-
vidual serum TCDD measurements are sig-
nificantly positively related to overall cancer Dioxin exposure and cancer risk
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incidence among women in the SWHS cohort. 
The results of this study are consistent with 
TCDD as a potent multisite carcinogen in 
animals and with increased cancer mortality 
risks reported in the male occupational cohort 
studies and used by IARC in its classification 
of TCDD (IARC 1997; Steenland et al. 2004). 
Thus, this study extends the results of the 
recent IARC reassessment to include women. 
SWHS women were 0–40 years of age at expo-
sure, and almost one-third of the women were 
premenarche at exposure. With continued 
follow-up of SWHS, we will begin to be able 
to examine the carcinogenic effects of TCDD 
during potentially susceptible windows of 
exposure such as premenarche or time between 
menarche and age at first full   pregnancy.
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